Statements (61)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:monoclonal_antibody
|
| gptkbp:bfsLayer |
6
|
| gptkbp:bfsParent |
gptkb:Crysvita
|
| gptkbp:activities |
inhibits FG F23 activity
|
| gptkbp:affects |
not fully established
|
| gptkbp:appointed_by |
subcutaneous injection
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:brand |
gptkb:Crysvita
|
| gptkbp:clinical_trial |
gptkb:Ultragenyx_Pharmaceutical
multiple countries Phase 3 improved quality of life reduced pain improved bone mineralization improved serum phosphate levels long-term management of XLH |
| gptkbp:contraindication |
hypersensitivity to burosumab
|
| gptkbp:developed_by |
gptkb:Ultragenyx_Pharmaceutical
|
| gptkbp:dosage_form |
solution for injection
|
| gptkbp:duration |
every 4 weeks
|
| gptkbp:effective_date |
2017-12-14
|
| gptkbp:first_introduced |
gptkb:2018
|
| https://www.w3.org/2000/01/rdf-schema#label |
burosumab
|
| gptkbp:indication |
treatment of XLH in children and adults
|
| gptkbp:invention |
patented
|
| gptkbp:is_monitored_by |
serum phosphate levels
|
| gptkbp:is_used_for |
X-linked hypophosphatemia (XLH)
|
| gptkbp:lifespan |
approximately 19 days
|
| gptkbp:marketed_as |
gptkb:legislation
gptkb:Australia gptkb:Japan gptkb:United_States gptkb:Native_American_tribe |
| gptkbp:pharmacokinetics |
linear pharmacokinetics
reduces serum FG F23 levels |
| gptkbp:population |
pediatric and adult patients
|
| gptkbp:receives_funding_from |
public and private sectors
|
| gptkbp:research_areas |
rare bone disorders
|
| gptkbp:rounds |
primarily renal
|
| gptkbp:safety_features |
generally well tolerated
|
| gptkbp:side_effect |
gptkb:fandom
fatigue headache nausea osteomalacia abdominal pain vomiting diarrhea rash injection site reactions toothache nasopharyngitis hypophosphatemia hyperphosphatemia arthralgia hypocalcemia pruritus dental abscess |
| gptkbp:storage |
refrigerated
|
| gptkbp:targets |
fibroblast growth factor 23 (FG F23)
|
| gptkbp:type_of_care |
important for treatment efficacy
|